Compare PNW & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PNW | PRAX |
|---|---|---|
| Founded | 1985 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electric Utilities: Central | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.1B | 9.6B |
| IPO Year | 1994 | 2020 |
| Metric | PNW | PRAX |
|---|---|---|
| Price | $99.63 | $292.64 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 15 |
| Target Price | $97.25 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 1.2M | 328.0K |
| Earning Date | 04-30-2026 | 05-01-2026 |
| Dividend Yield | ★ 3.69% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 5.05 | N/A |
| Revenue | ★ $5,339,939,000.00 | N/A |
| Revenue This Year | $5.24 | N/A |
| Revenue Next Year | $6.67 | $6,395.88 |
| P/E Ratio | $19.51 | ★ N/A |
| Revenue Growth | ★ 4.20 | N/A |
| 52 Week Low | $85.32 | $26.70 |
| 52 Week High | $103.97 | $354.87 |
| Indicator | PNW | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 52.20 | 42.38 |
| Support Level | $86.96 | $289.02 |
| Resistance Level | $103.59 | $322.32 |
| Average True Range (ATR) | 1.77 | 16.26 |
| MACD | -0.57 | -0.68 |
| Stochastic Oscillator | 40.86 | 17.75 |
Pinnacle West is a holding company whose principal subsidiary is Arizona Public Service, a vertically integrated electric utility serving approximately 1.4 million customers across a 35,000-square-mile territory in central Arizona, including the Phoenix area. APS owns or leases 6.5 gigawatts of power generation capacity, including a 29% ownership stake in one of the largest nuclear plants in the US, Palo Verde. Half of the electricity that APS supplies to customers comes from clean energy sources, including nuclear.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.